• Continued strong demand for PhotonAssay with sample volumes approaching 1 million per month
• 41 PhotonAssay units deployed globally, with two new lease agreements and four upcoming installations
• Reiterated FY26 guidance of $80-90m revenue and $20-27m EBITDA

Chrysos Corporation Ltd presented its 2025 AGM, highlighting the continued strong demand for its PhotonAssay technology. The company reported sustained PhotonAssay sample volumes approaching 1 million per month, with increased monthly throughput consistently between 50-100% year-over-year. The industry outlook remains positive, supported by a strong gold price, exploration activity, and production outlook.Chrysos has deployed 41 PhotonAssay units globally to date, with two additional units deployed in FY26. The company has also signed two new lease agreements and has four upcoming installations, showcasing the strong global demand and continued diversified customer growth.Financially, the company reported unaudited YTD revenue of $28.9 million, comprising $21.2 million in MMAP and $7.6 million in additional assay charges. The company reiterated its FY26 guidance of a revenue range of $80 million to $90 million and an EBITDA range of $20 million to $27 million.The presentation also covered Chrysos' research and development roadmap, focused on advancing the company's capabilities to enable sustainable growth. Key areas include improving quality, resilience, and performance, as well as broadening the offering to include new elements and technologies beyond the core gold, silver, and copper analysis.

FY26 Total Revenue range of $80m to $90m, FY26 EBITDA range of $20m to $27m

Chrysos remains focused on advancing its research and development to further enhance its PhotonAssay technology and expand its offering to new elements and complementary analysis capabilities. The company is also exploring opportunities to integrate sample preparation and analysis to provide a more end-to-end service, particularly for mine-site installations.